Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
Abbott Receives CE Mark for Company's Next-Generation XIENCE PRIME Drug Eluting Stent, Advancing Leadership Position
Abbott, 06/24/09
Abbott announced that it has received CE Mark for its next-generation XIENCE PRIME Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. The company plans to launch XIENCE PRIME in a broad size matrix with lengths up to 38 mm in Europe in the third quarter.
Today in Cardiac/Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia
Current Medical Research and Opinion, 12/18/09
Grip strength and cardiovascular drug use in older people: findings from the Hertfordshire Cohort Study
Age and Aging, 12/18/09
Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia
Lipids in Health and Disease, 12/18/09
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 2010
Cell Therapeutics, 12/18/09
Sanofi Pasteur obtains license from Syntiron to develop & commercialize vaccine to prevent Staphylococcus infections
Sanofi-aventis, 12/17/09
Telmisartan/amlodipine: approved for high blood pressure
Formulary , 12/16/09
Today in Drug/Product Alerts...keeping you current
Receive free subspecialty "5-minute updates" via email
Generic drugs dominate market, look to expand into biologics
Formulary , 12/16/09
Mylan Receives Approval for Generic Version of Antiepileptic Keppra 1000 mg
Mylan, 12/15/09
Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval
Expert Opinion in Pharmacotherapy, 12/09/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


